Cannabis Law and Access in Portugal

Portugal's cannabis framework: what the 2001 law actually did , and didn't do

Twenty-three years on, Portugal's drug policy experiment is still routinely misread. The short version is: Portugal decriminalised personal possession of all drugs in 2001, including cannabis. But decriminalisation is not legalisation, supply remains a criminal matter, and a separate medical cannabis framework was introduced in 2018 under quite different rules. The distinction matters, and I'll come back to it.

I was flicking through a vintage 1972 road atlas of Iberia last month , part of a completely unrelated project, don't ask , and it struck me how often the "Portugal is the drug-reform success story" narrative gets attached to a single data point, as if one legislative moment explains everything. The actual legal architecture is layered, frequently revised, and worth reading carefully before drawing conclusions.

For Australian readers: none of this is Australian law. Cannabis in Australia is regulated under the Commonwealth Poisons Standard and state/territory legislation. Access to medicinal cannabis here goes through the TGA's Special Access Scheme, the Authorised Prescriber pathway, and the ARTG listing process. The Portuguese framework described below is a separate sovereign legal system and has no bearing on what is lawful in Australia.

Law 30/2000: what decriminalisation actually means in Portuguese law

Lei n.º 30/2000 came into force on 1 July 2001. Under that law, personal possession of any illicit substance; up to a defined threshold quantity, was removed from criminal law and reclassified as an administrative offence. For cannabis, the threshold is defined by reference to a ten-day personal supply, which Portuguese authorities have interpreted as approximately 25 grams of herb or 5 grams of hashish. Possession at or below those amounts triggers a referral to a Comissão para a Dissuasão da Toxicodependência (CDT), a Dissuasion Commission; rather than a criminal prosecution.

The CDT is a three-person panel, typically including a legal professional, a social worker, and a health professional. It can impose administrative sanctions: fines, community service, licence suspensions, or mandatory treatment referral (though treatment cannot be compelled). First-time offenders with small quantities often receive a suspended sanction.

Crucially, possession above the threshold, and all supply, trafficking, and cultivation for supply, remain criminal offences under Lei n.º 15/93 (the Narcotics Law). A person found with 30 grams is in a very different legal position to one found with 20. The line is administrative, and Portuguese prosecutors do exercise discretion on either side of it.

So the widely repeated claim that "Portugal legalised drugs" is simply wrong. Cannabis is not a legal commodity in Portugal for recreational purposes. There is no licensed recreational market, no retail, no regulated supply chain for non-medical use. Understanding tetrahydrocannabinol as a controlled compound helps explain why the supply side remains firmly criminal, THC is the primary scheduled constituent in most jurisdictions, and Portugal's Narcotics Law has not changed that position.

The 2018 medical cannabis law: Decree-Law 8/2019

A separate and later development is Portugal's medicinal cannabis framework, established through Law 33/2018 and given operational form by Decree-Law 8/2019. This created a licensing regime for the cultivation, production, and export of cannabis for medicinal and scientific purposes, administered by INFARMED, the Autoridade Nacional do Medicamento e Produtos de Saúde, roughly equivalent to the TGA in function.

Under this framework, pharmaceutical-grade cannabis products can be prescribed by physicians and dispensed through licensed pharmacies. The products must meet standards for quality and consistency. INFARMED oversees licensing of producers and importers, and the rules align in structure (though not in detail) with European Medicines Agency guidance.

What this does not create is a wide-open prescribing market. Physicians operate under professional guidelines, products must hold relevant authorisations, and the framework is oriented toward pharmaceutical products rather than dried flower in the first instance; though the regulations have been interpreted to permit certain preparations. Portugal has also become a significant cannabis cultivation and export jurisdiction within the EU, with several licensed producers operating under INFARMED oversight.

For readers familiar with the Australian model: the Portuguese medical system has some structural parallels with how the TGA's Schedule 4 and Schedule 8 distinction works in terms of differentiating access pathways by product type and concentration, though the specific rules are different. Products containing significant cannabidiol concentrations sit differently in the Portuguese framework than those with higher THC content, much as CBD and THC carry different scheduling weight here.

Regulation of hemp and low-THC cannabis

Portugal, as an EU member state, is bound by EU regulations on industrial hemp. Varieties with THC content below 0.2% (the EU threshold at the time of writing, though the EU debated revision to 0.3%) can be cultivated under licence for industrial and agricultural purposes. CBD products derived from such hemp occupy a complicated space across the EU, the Novel Food Regulation has been the primary regulatory instrument, with the European Food Safety Authority assessing CBD as a novel food ingredient.

This means that broad-spectrum or isolate-based CBD products sold in Portuguese health shops and pharmacies may be positioned as food supplements, subject to Novel Food rules, rather than as medicines; a familiar ambiguity to anyone watching the regulatory treatment of CBD in the UK and elsewhere. The medical claim/food supplement boundary is actively policed by INFARMED.

Possession, tourism, and real-world enforcement

Lisbon's Rua do Arsenal and the streets around Cais do Sodré are well-known to backpacker circuits, and the gap between legal framework and street-level reality is worth acknowledging honestly. The decriminalisation framework means that a tourist found with a small amount faces an administrative process, not automatic arrest and criminal charge. But "no criminal charge" is not "no consequence", fines, confiscation, and a CDT appearance are real outcomes. Foreign nationals are not exempt. And behaviour that attracts attention at volume or suggests supply rather than personal use will be treated differently.

I'd argue the popular tourism narrative sometimes elides this in a way that does travellers a disservice. The framework is relatively humane by international standards, but it is not a green light, and the CDT process is not nothing.

What this means in an Australian regulatory context

Australian researchers, policymakers, and practitioners who look at the Portuguese model tend to focus on its public health outcomes, drug-related HIV infection rates, incarceration rates, treatment uptake. That's legitimate comparative policy research. But the legal architecture itself does not translate across. Australia's scheduling framework, the Poisons Standard, state and territory drug laws, and the TGA's access pathways are sovereign instruments. A substance's status in Portugal has no bearing on its status here.

Anyone in Australia seeking information about lawful access to medicinal cannabis should engage with the TGA's published guidance, including the Special Access Scheme Category B process, the Authorised Prescriber pathway, and what it means for a product to be listed on the ARTG. Those are the operative frameworks. The Portuguese comparison is useful as policy context; it is not a guide to what is available or lawful here.

For background on the pharmacology that underlies much of this policy discussion; including how endocannabinoid system research has informed scheduling decisions internationally, our glossary covers the relevant science. The political decisions about where THC and CBD sit in any given country's law are ultimately downstream of both chemistry and political economy, in proportions that vary by jurisdiction.

Portugal remains a genuinely interesting case study in drug law reform. It is not, as sometimes claimed, proof that anything goes. The real lesson is probably more modest: that administrative rather than criminal consequences for personal possession can coexist with a functional society. Whether that lesson transfers, and how, is a policy question each jurisdiction answers for itself.

Sources

• Portugal Drug Report 2023, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
• INFARMED; Autoridade Nacional do Medicamento e Produtos de Saúde (Portugal)
• Medicinal Cannabis: Information for Patients and Caregivers, TGA (Australia)
• Drug decriminalisation in Portugal: setting the record straight, BMC Public Health via NCBI

, Marcus Hale, Regulatory researcher; TGA & access law